Joseph Ebinger
Cardiovascular Disease · San Francisco, CANPI 1245529940
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,994 of the $7,994 with a category attached, or 100.0%. Edwards Lifesciences accounts for 64.7% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $2664.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$5K
- Astrazeneca UK Limited$3K
Across 7 payments — averaging $26,928 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$188K
What the payments were for
- Consulting fees$7,994100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 2 | $5,175 |
| Astrazeneca UK Limited | 1 | $2,819 |
How this compares
$7,994 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $19,240 |
| Repatha SureclickEvolocumab | 12 | $12,155 |
| EntrestoSacubitril/Valsartan | 12 | $10,364 |
| FarxigaDapagliflozin Propanediol | 12 | $7,095 |
| Potassium Chloride | 13 | $453 |
| Telmisartan | 15 | $447 |
| Metoprolol Succinate | 35 | $321 |
| Atorvastatin Calcium | 51 | $285 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 14 | $269 |
| Chlorthalidone | 13 | $216 |
| Carvedilol | 22 | $149 |
| Losartan Potassium | 11 | $119 |
| Spironolactone | 25 | $96 |
| Lisinopril | 19 | $68 |
| Rosuvastatin Calcium | 24 | $57 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in San Francisco
- Philip SagerSan Francisco$675K
- Javid MoslehiSan Francisco$307K
- Tony ChouSan Francisco$301K
- Lloyd KleinSan Francisco$149K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.